Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation.
about
Histone Deacetylases and Their Inhibition in Candida SpeciesThe Set3/Hos2 histone deacetylase complex attenuates cAMP/PKA signaling to regulate morphogenesis and virulence of Candida albicansThe Candida albicans Histone Acetyltransferase Hat1 Regulates Stress Resistance and Virulence via Distinct Chromatin Assembly PathwaysCandida albicans SET1 encodes a histone 3 lysine 4 methyltransferase that contributes to the pathogenesis of invasive candidiasis.Low dosage of histone H4 leads to growth defects and morphological changes in Candida albicansIdentification of a key lysine residue in heat shock protein 90 required for azole and echinocandin resistance in Aspergillus fumigatus.HOS2 and HDA1 encode histone deacetylases with opposing roles in Candida albicans morphogenesis.Release from quorum-sensing molecules triggers hyphal formation during Candida albicans resumption of growth.Functional characterization of Candida albicans Hos2 histone deacetylase.A genomewide screen in Schizosaccharomyces pombe for genes affecting the sensitivity of antifungal drugs that target ergosterol biosynthesisModulation of morphogenesis in Candida albicans by various small molecules.Regulatory circuitry governing fungal development, drug resistance, and disease.Evaluation of reference genes for real-time quantitative PCR studies in Candida glabrata following azole treatment.Histone deacetylase inhibition as an alternative strategy against invasive aspergillosis.Synergy of flavonoids with HDAC inhibitor: new approach to target Candida tropicalis biofilms.Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus speciesIsolation of Vaginal Lactobacilli and Characterization of Anti-Candida Activity.The challenge of managing fusariosisCyclic AMP signaling pathway modulates susceptibility of candida species and Saccharomyces cerevisiae to antifungal azoles and other sterol biosynthesis inhibitors.An update on antifungal targets and mechanisms of resistance in Candida albicans.The therapeutic uses of chromatin-modifying agents.Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals.Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor.Extensive functional redundancy in the regulation of Candida albicans drug resistance and morphogenesis by lysine deacetylases Hos2, Hda1, Rpd3 and Rpd31.Combinatorial strategies for combating invasive fungal infections.Antifungal adjuvants: Preserving and extending the antifungal arsenalChromatin-mediated Candida albicans virulence.Small-molecule chromatin-modifying agents: therapeutic applications.Heat shock protein 90 (Hsp90): A novel antifungal target against Aspergillus fumigatus.Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies.Candida Efflux ATPases and Antiporters in Clinical Drug Resistance.Histone deacetylases inhibitors effects on Cryptococcus neoformans major virulence phenotypesLysine deacetylases Hda1 and Rpd3 regulate Hsp90 function thereby governing fungal drug resistance.A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.Effects of cetylpyridinium chloride resistance and treatment on fluconazole activity versus Candida albicans.Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.Novel hydroxamates potentiated in vitro activity of fluconazole against Candida albicans.Fungi treated with small chemicals exhibit increased antimicrobial activity against facultative bacterial and yeast pathogens
P2860
Q26740146-C5AFD106-4FD7-4B2D-AAEE-FDCE0665FCDFQ28473928-B0D52304-37A7-44C7-8354-95992307B5F2Q28550375-3F15AAF2-3F6B-4B2D-B284-5AB6228D8018Q33240623-FDE99F95-A7E4-4285-8AA2-2AF4229E93A5Q33586127-AB8450DB-79E8-443B-B0D9-F03D31EAADB8Q33622943-89DA8132-0CDC-4B3A-8E80-A590CE50B62BQ33668741-FD807A8A-D333-4E50-BB61-65FA47F80246Q33884500-FFCF9145-C308-48C7-AD08-C5908B313575Q33950770-6BC2CC38-B90E-4E17-9E46-8F36C62FF366Q34129971-73DEE564-6361-40E0-8DAE-21233F035996Q34189952-7A51B3FB-3A13-4F7C-BFE3-23C2158E13B3Q34190284-1179CBAF-2740-435A-9952-759AB7557B6AQ34322237-AF1E153A-8F4C-4257-B35A-E3353796EB79Q35087299-5939318F-8142-4650-9F68-AA6A3354AB5AQ35142574-A9CE7AD9-5654-4E65-97AC-BEA8205F011FQ35214605-7B4DE1FD-A7DA-4299-90CA-580C023B8429Q35670618-8790AC96-6B35-48B1-9523-17D0E391277BQ35693680-30BA022A-CCC9-4F35-B08D-47956E5338A3Q36048538-6078AA7B-A2C8-43FE-A5FC-39A6C9BAF839Q36235037-F7085B03-55EB-489E-B426-BBCA59DDB236Q36822457-B1065EB7-F1FC-4FC2-B16C-20AA8E1DB897Q37274696-FA7E9A15-8847-4682-A12D-17B50FC294EFQ37568607-95F02A97-2F4E-4BA7-BB47-5A2F3B1F5536Q37568906-7FE5FEFB-E24B-4C16-B4A5-B8FAA396A203Q37629735-B743848C-2ADB-4D4C-9BCD-A48788B41AFBQ37705303-D058F765-A3D5-45FC-B603-AF400EE1080CQ37705308-AFD1B165-E3D5-4CB1-B332-864CF3804DB0Q37925912-90682F37-F264-4CCE-8C4B-17472FD5EA5FQ37961728-12DB1C44-7010-4473-9AEA-5DCA8E36F9E2Q38253077-4D0B2039-E0BA-4C69-9E08-32EB4D11FDA4Q38311999-A3B4D9A2-FDBF-4BB0-AC6C-F75432884AD0Q38684284-B80C8C56-306A-4DE0-B6B3-48F0B6999BD9Q38919839-113059E2-1059-4026-9F23-8DF05D0A3915Q39260998-08983221-4341-4978-B03F-A1B6297495FEQ39686624-A4917526-7517-49B5-9E86-6D887F8850F9Q41007855-E281A603-A52B-45D6-A893-A90E45CEBFD2Q41908299-06D0F41A-59D2-46DF-B1BF-E7D845DC56AFQ41957394-5716FBCE-9E2F-46BA-A5AB-5F4C7624C73AQ41967401-BB91CE73-8E29-4EF7-8CED-0F751280C36CQ42048601-FE448416-C8D1-4224-9684-2D3ECCDD9D3E
P2860
Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Histone deacetylase inhibitors ...... n in CDR and ERG upregulation.
@en
Histone deacetylase inhibitors ...... n in CDR and ERG upregulation.
@nl
type
label
Histone deacetylase inhibitors ...... n in CDR and ERG upregulation.
@en
Histone deacetylase inhibitors ...... n in CDR and ERG upregulation.
@nl
prefLabel
Histone deacetylase inhibitors ...... n in CDR and ERG upregulation.
@en
Histone deacetylase inhibitors ...... n in CDR and ERG upregulation.
@nl
P2860
P1476
Histone deacetylase inhibitors ...... n in CDR and ERG upregulation.
@en
P2093
Thomas D Edlind
W Lamar Smith
P2860
P304
P356
10.1128/AAC.46.11.3532-3539.2002
P407
P577
2002-11-01T00:00:00Z